A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

This is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in participants with B-cell malignancies post CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 and timing of administration will be evaluated in Phase I in order t

Trial Details

NCT ID
NCT06045910
Phase
PHASE1 / PHASE2
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • ALETA-001
Locations (sample)
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Cambridge, United Kingdom|52.2,0.11667
  • Leeds, United Kingdom|53.79648,-1.54785
  • London, United Kingdom|51.50853,-0.12574
  • Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

  • For all participants
  • Criteria to be met prior to enrolment in the trial:
  • Aged 16 years or over.
  • Written (signed and dated) informed consent and be capable of co-operating with ALETA-001 administration and follow-up.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →